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Abstract: Lateral flow assays (LFAs) are the mainstay of rapid point-of-care diagnostics, with the
potential to enable early case management and transform the epidemiology of infectious disease.
However, most LFAs only detect single biomarkers. Recognizing the complex nature of human
disease, overlapping symptoms and states of co-infections, there is increasing demand for multiplexed
systems that can detect multiple biomarkers simultaneously. Due to innate limitations in the design of
traditional membrane-based LFAs, multiplexing is arguably limited to a small number of biomarkers.
Here, we summarize the need for multiplexed LFA, key technical and operational challenges for
multiplexing, inherent in the design and production of multiplexed LFAs, as well as emerging
enabling technologies that may be able to address these challenges. We further identify important
areas for research in efforts towards developing multiplexed LFAs for more impactful diagnosis of
infectious diseases.
Keywords: lateral flow assay; point-of-care; multiplex; diagnostic test; infectious disease; resource-
limited settings
1. Needs and Impetus for Multiplexed Lateral Flow
In resource-constrained settings where lack of access to laboratories constitutes a critical gap in
delivering healthcare services, point-of-care (POC) rapid diagnostics adopted with appropriate linkage
to health systems have led to faster test-to-result turnaround time, reducing loss to follow up and
enabling prompt case management [1]. Among the most familiar of POC formats are lateral flow
immunoassays (LFAs), which are typically qualitative diagnostic tests to determine the presence or
absence of a target analyte within a non-invasive sample such as whole blood or urine [2].
However, in such settings where lateral flow POCs have prevailing advantages over more
sophisticated but laboratory-confined diagnostics, infectious diseases of concern such as tuberculosis,
malaria, and parasitic helminthes may share similar symptoms with viral and/or bacterial illnesses,
and an individual patient may harbor several co-infections [3]. As such, some public health strategies
have often been criticized for being too disease-specific, and not necessarily addressing the overall
health of the individual. Indeed, sustainable control strategies, including disease elimination,
are likely to require integrated approaches and enabling diagnostic tools that break away from
single-disease–single-test approaches that do not account for overall health needs of people living in
resource-constrained settings [4]. Although the current evidence base is sparse, such tools arguably
have increased impetus for scale-up due to wider market relevance and potential cost-effectiveness.
However, more importantly, tests that are able to diagnose or rule out key infections within one
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interaction at POC may facilitate more pertinent management of the frequently complex nature
of patient morbidity. Given economic constraints faced by health programs worldwide, as well as
increasing demands for decentralized health care, such tests would arguably be attractive even in
higher income settings.
Improved case management of diseases with common symptoms is especially crucial in areas
with dense populations where explosive epidemics may occur (such as refugee camps) [5], for prompt
discrimination of an endemic infectious disease versus the beginning of an epidemic. The West African
Ebola virus outbreak in 2014 was notably difficult for healthcare workers to identify in its early stages
due to confusion with malaria, shigellosis, and salmonellosis [6], with higher patient deaths associated
with longer referral pathway [7].
Additionally, some infections for which active infection has been difficult to screen serologically
such as tuberculosis may require the detection of multiple biomarkers such as combining detection of
antigen-specific antibodies and antigens to reach acceptable levels of sensitivity [8,9].
Arising from these needs, the demand for multiplexed diagnostics has become more pressing.
Microfluidic biosensors are a natural platform for multiplexed diagnostics due to the minute size of
micro-systems and microarray capacity [10]. Indeed, there have been several reports of various tests
able to detect multiple analytes on lab-on-a-chip devices with high accuracy [11]. However, these
successes in the laboratory are yet to be scalable to reach end-user market due to challenges in mass
production, particularly sensor fabrication costs, which limits their translation into POC tests. Given
the demand for multiplexed testing and prevailing advantages of the LFA over alternative rapid
diagnostic platforms for resource-constrained settings [12], this article aims to address the question of
whether the so-called simplicity of membrane-based LFA may be adaptable to multiplexed formats.
2. Challenges and Emerging Technologies in Multiplexing LFAs
LFAs are membrane-based platforms typically used to qualitatively detect targeted analytes
in complex samples within 5–30 min [13]. LFAs are currently the only rapid diagnostic format
that fully meets the World Health Organization (WHO)’s ASSURED (affordable, sensitive, specific,
user-friendly, rapid and robust, equipment-free and deliverable to end users [14]) criteria for testing
in resource-constrained settings. These qualities also have seen LFAs become ubiquitous in various
settings including hospitals, public and private clinics and laboratories.
Despite decades of use, improvement of this format remains in its infancy. Significant efforts have
been made at improving LFA sensitivity and specificity; however, the most coveted iteration of the
LFA would be able to measure multiple biomarkers simultaneously [15]. Presently, few multiplexed
LFAs exist in the market and the vast majority of these are developed to detect toxins, drugs and more
general clinical biomarkers such as liver enzymes, cardiac and hematological markers. Multiplexing
of infectious disease biomarkers has apparently been complicated by the inherent limitations in the
LFA system and platform. LFAs predominantly use immobilized antibodies or proteins as capture
ligands placed at specific locations (typically striped as a line) across a membrane, and in-solution
detector molecules typically labeled with colloidal gold. While largely versatile, rapid, with potential
for high accuracy, this system is also susceptible to drawbacks such as lot-to-lot variability, antibody
cross-reactivity, and dependence on capillary action between sample and LFA strip components [2,16].
Any multiplexed formats utilizing traditional immunoassay principles would be expected to overcome
the compounded technical challenges of single-biomarker LFAs in order to be useful and scalable [17].
The technical challenges of multiplexing LFAs have been extensively reviewed elsewhere [15,18],
but the main concern appears to be potential cross-reactivity, which limits the number and types
of biomarkers that can be combined. Cross-reactivity, which causes non-specific binding, higher
background and/or false positives, has been observed for several infectious diseases such as
flavivirus infections (dengue with zika virus) [19] and helminthic infections (strongyloidiasis with
filariasis) [20], which incidentally may also have overlapping symptoms. Multiplexing several test
lines on a single LF strip is also confined to physical limits, the number of conjugates, as well as
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the flow changes when passing through multiple lines. Arguably, these physical limitations may be
circumvented using recently reported creative designs using multiple strips [21,22], spot arraying
within the test field of the LF membrane, a pixelation technology currently commercially offered by
Symbolics LLC [23], or optically encoded regions embedded within a porous membrane [17]. Further
operational and quality assurance issues exist, primarily related to adapting available designs of
assay evaluations (particularly the use of appropriate patient and control populations), methods of
calibration, validation and assessment of diagnostic accuracy and reproducibility that have been
established for single-biomarker LFAs [18]. The “simplicity” of LFAs that allow for minimal training
may be compromised if multiple results need to be interpreted on a single test; however, this too
may be addressed with the increasing availability of portable battery-operated instruments and smart
devices. In addition, many good biomarkers that are available in single-test LFAs, are proprietary
and/or patented, and maneuvering proprietary interests of different parties who may not be readily
willing or able to share their technology may pose additional challenges.
From a research perspective, there have been encouraging reports of multiplexed LFA prototypes
in recent literature. Notable mentions include (1) multiplexed LFA developed using multi-colored silver
nanoparticles (AgNPs) to give colored test lines for simultaneous detection of dengue, yellow fever,
and Ebola viruses [24]; (2) a novel disc design incorporating 10-dipsticks lined with 10 different
foodborne pathogen biomarkers using up-converting phosphor (UCP) particle as the reporter
for increased sensitivity and tolerance of sample interference [21]; (3) an LFA also utilizing the
UCP technology to detect multiple cytokines in leprosy [25] and (4) an LFA-based multiplex for
diagnosing acquired immune deficiency syndrome (AIDS), and hepatitis C and A (HAV, HCV) using
proteinticle-based 3D probes that display different viral antigens [26].
Despite these developments in the literature, very few multiplexed LFAs have become commercial
products [12], suggesting the existence of critical challenges that impede the translation of multiplexed
LFAs beyond laboratory research scale. Table 1 briefly summarizes the key challenges in the path
of producing a multiplexed LFA diagnostic product that can reach the end-user market, broadly
categorized as (1) technical or assay development and (2) quality control and operational, and appraises
whether there is scope to overcome these challenges with consideration of recent developments and
emerging enabling technologies (Table 1).
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Table 1. Assessment of challenges in multiplexing lateral flow assays (LFA).
Challenge Difficulty * Remarks References (No.)
Technical and
Assay Development
Cross-reactivity of immobilized capture and
detector antibodies with non-targeted analytes
limits multiplexing capability. Antibodies that have
been validated on single-assays may be
cross-reactive when multiplexed with other assays.
Some proteins may not be usable due to nonspecific
binding which may reduce assay sensitivity.
Possible
Aptamer oligonucleotides are reportedly cheaper
than antibodies. Dual recognition element LFA
(DRELFA) has been shown to overcome cross-reactivity
of antibody and slow-binding kinetics of aptamers.
Phage-display derived recombinant antibodies with
potential for higher specificity.
Proteinticles (genetically modified proteins) used as
3D probes demonstrate increasing sensitivity of
multiplexed LFA for anti-viral detection in HIV,
HAV, and HCV.
Lee, et al. [26]
Le, et al. [27]
Ch’ng, et al. [28]
Physical limitation of LFA strip to only a few test lines
placed at specific locations, the number of which will
affect the test flow rate.
Possible
Pixelation technology for spot array commercially available
to test developers since 2015.
Parallume lanthanide optical encoding technology enables
deep optical multiplexing using a companion reader,
proof-of-concept demonstrated for multiplex detection of
anti-HIV, anti-HCV etc.
Multiple strips incorporated in disc design, allowing
detection of 10 different biomarkers simultaneously.
O’Farrell, et al. [15]
Haushalter, et al. [17]
Zhao, et al. [21]
Clinical specimens for assay development and test
validation will require patients with multiple
co-infections relevant to the test, which may be
difficult to acquire.
Difficult-Possible
Available cohort studies monitoring and diagnosing several
diseases relevant to the local epidemiology may be an
important source of specimens with relevant co-infections.
Hook effect arising from an excess of unlabeled
analytes competing with labeled analytes causes
decrease in test signal for samples with high analyte
concentration. Compounded in multiplexed assays
with cross-reactivity.
Possible
With the use of a portable imaging devices, a reaction
kinetics-based technique (example: C-reactive protein) has
been proposed to significantly increase the dynamic range
of LFAs, overcoming the problem of hook effect.
Rey, et al. [29]
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Table 1. Cont.
Challenge Difficulty * Remarks References (No.)
Operational and
Quality Control
Inter- and intra-assay variability (estimated by
coefficient of variation (CV)) for multiplexed test are
questionable and acceptable values of reproducibility
in multiplexed tests undefined. Difficult
Limited guidance/regulation available for development of
multiplexed LFAs may require more concerted effort from
authoritative diagnostic and regulatory bodies.
Ellington, et al. 2010 [18]
Acceptable level of imprecision of LF assays undefined.
Unclear whether failure of one test within the multiplex
constitutes entire test failure.
Conventional LFAs with visual interpretation become
complicated with increasing number of test results and
corresponding controls, particularly with positive
results with low signals.
Possible
Test results may be varied using different labels
(e.g., multicolored silver particles), or structures/shapes.
Portable battery-operated readers, smartphones with
diagnostic applications or accessories (dongles) are
becoming readily available to remove reliance on
user-interpretation, and allows for alternative probes
and also produce data for analytical and monitoring.
Yen, et. al. [24]
Martinez-Hurtado, et. al., [30]
Guo, et al. [31]
Laksanasopin, et al. [32]
* Judgment on degree of challenge difficulty to overcome marked as Difficult or Possible with consideration of current developments, trends and new/alternative technologies/materials
in the literature.
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3. Way Forward
From a technical perspective, the literature indicates that multiplexing on LFA may require
capture and detector systems that move away from conventional monoclonal antibodies and proteins.
While the examples provided focused on multiplexed LFAs for multiple diseases, we expect the
challenges and opportunities discussed to be applicable for multiplexed LFAs designed to detect a
panel of biomarkers for diagnosis of a single infectious disease. In particular, alternative biomolecules
such as aptamers, recombinant antibodies, and engineered protein scaffolds are expected to have
more capacity to overcome any potential cross-reactivity within and between assays combined on one
multiplexed LFA test [26–28]. The critical issue here is whether there will be access to these alternative
biomolecular reagents from commercial sources, particularly for LFA developers without collaborative
links to research groups producing these reagents. For example, the development of aptamers through
SELEX (systematic evolution of ligands by exponential enrichment) requires high initial investment
and specialized skills. This limits the number of groups that can exploit this approach, and prevents
developers from delving into multiplex LFA formats for detecting biomarkers. This is in contrast to the
current scenario for developers using monoclonal antibodies, which are quality assured and produced
against an array of targets available for order on a supplier’s catalogue, speeding up the process for
diagnostic research and development. Hence, before multiplexed LFA can become a reality, these
promising biomolecular alternatives first need to be accessible and reach the scale of mass production.
Similarly, many reports on multiplexed LFA in recent literature utilized alternative probes and
detection systems that are more amenable to multiplexing with the support of readers [17,24,29,30].
Although ASSURED criteria recommend equipment-free POC diagnostic tests, portable battery-operated
readers and smartphones with special applications are becoming more readily available to remove
reliance on user-interpretation. Among the more promising examples is a low-cost cell phone-based
dongle platform able to perform the functions of a reader solely requiring energy from the connected
smartphone [31,32]. On top of facilitating interpretation of multiplexed LFA test results, these instruments
have the capacity to collect data for analytical and monitoring purposes. Such data collection and
monitoring would be even more critical to evaluate the performance of these more complex LFA tests in
the field over time. The advent of Internet of things (IoT) further allows the test results to be quickly
transmitted to the relevant agencies, especially for notifiable diseases. While this can be a positive
development for monitoring and surveillance, it also brings forth new challenges such as regulatory
requirements in the handling and safety of the data [12]. Regardless, the use of any form of reader is
anticipated to increase the overall price of the test, which may be a contentious issue for adoption in
resource-constrained settings. Without reliance on readers for interpretation of test results, multiplexed
LFA may require creative designs [21,23], or alternative labeling methods such as using shapes or
multicolored nanoparticles [24]. Either of these approaches will require a transdisciplinary approach,
with key skillsets in biotechnology, chemical engineering, software/application programming, industrial
design and collaboration with industry partners.
Arguably the most difficult hurdles to overcome lie in validation, commercial translation and quality
assurance of any multiplex LFA device that shows promise in the laboratory or research scale. Furthermore,
validation of diagnostic accuracy and reproducibility will require judicious study designs, and critically
so, access to single-infection and co-infection patient samples and appropriate control samples. Where
single-test assays could utilize the coefficient of variation (CV) (ratio of the standard deviation to the
mean average) as a measure of intra- and inter-assay variability, it remains questionable whether the
CV is still usable for multiplex tests, as well as the range of values of acceptable precision or inaccuracy.
Validation studies of other platforms such as multiplex chemiluminescent immunoassays suggest that
while intra-assay CVs for multiplex may be comparable with single ELISAs, inter-assay CVs indicate
higher variability between the multiplex assays [33,34]. Recommendations recently exist for validation of
multiplex tests in drug development [35], with considerations for construction of a biomarker work plan,
the number of analytes in one test, and the alignment of statistical acceptability criteria with intended use,
and clinical, biological, and epidemiological relevance of analyte(s). While these recommendations may be
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applicable for diagnostic applications, developers may rely on authoritative bodies in diagnostics such as
the Foundation for Innovative New Diagnostics (FIND) and PATH and regulatory bodies such as the Food
and Drug Administration (FDA) to address the many uncertainties with regards to ascertaining diagnostic
accuracy and reproducibility. Figure 1 highlights the factors that may promote efforts towards successful
development and translation of a multiplexed LFA.
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